Hypoparathyroidism Treatment Market is expected to grow at a CAGR of 8.3% during the forecast period and market is expected to reach US$ 1.78 Bn. by 2029. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding the global hypoparathyroidism treatment market dynamics, structure by identifying and analysing the market segments and project the global market size.To know about the Research Methodology :- Request Free Sample Report The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the global gram hypoparathyroidism treatment market. Hypoparathyroidism treatment market is projected to be a big market during the forecast periods, as the current population over the globe are suffering from hypoparathyroidism, Such as a report published by Endocrine Society in 2022, it was 60-8,500 patients in the U.S are suffering from hypoparathyroidism. Hypoparathyroidism is the decreased secretion or activity of parathyroid hormone resulting in low blood levels of calcium & higher levels of blood phosphorus. The growing incidence of neck, head and thyroid cancers is the other factor expected to drive the growth of the market. Increasing investments in the research and development coupled with the development of biologics are anticipated to generate momentum and growth opportunities for the global hypoparathyroidism treatment market. An oral segment is leading the market hypoparathyroidism treatment based on the route of administration. Oral calcium supplements can raise calcium levels in your blood. Though, at high doses, calcium supplements can cause gastrointestinal side effects, such as constipation, in some people. Vitamin D analogue segment is dominating the hypoparathyroidism treatment market. Vitamin D analogue must bind fit to the VDR to exert therapeutic actions. The basic structural portion of the vitamin D compound for VDR binding is the A-ring containing the 1α-hydroxyl group. High doses of vitamin D, usually in the form of calcitriol, can help the human body absorb calcium and eliminate phosphorus. Region-wise, North America has the largest market share for the global hypoparathyroidism treatment market. In the North America hypoparathyroidism treatment market, the US is anticipated to be the dominant country as it is a large economy and with high purchasing power. Also, favourable reimbursements for hypoparathyroidism treatment is also expected to support the growth of the hypoparathyroidism treatment market.
Hypoparathyroidism Treatment Market: Inquire before buying
Hypoparathyroidism Treatment Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 1.02 Bn. Forecast Period 2023 to 2029 CAGR: 8.3% Market Size in 2029: US $ 1.78 Bn. Segments Covered: by Drugs class Parathyroid hormone Vitamin D analogue Calcium supplements by Roots of Administration Oral Parenteral by Distribution Channel Retail pharmacy Hospital pharmacy Online sales Global Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Key Players
1. Shire-NPS Pharmaceuticals, Inc. 2. F. Hoffmann-La Roche Ltd. 3. EnteraBio Ltd. 4. WCCT GLOBAL INC. 5. Takeda Pharmaceutical Company Limited 6. Novartis AG 7. GlaxoSmithKline plc. 8. AbbVie Inc. 9. Sun Pharmaceuticals Ltd. 10. Teva Pharmaceuticals Ltd. 11. Amgen Inc. 12. Ascendis Pharma A/S Manufacturers Frequently Asked Questions: 1. Which region has the largest share in Global Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Market? Ans: The Global Hypoparathyroidism Treatment Market is growing at a CAGR of 8.3% during forecasting period 2023-2029. 3. What is scope of the Global Market report? Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Market? Ans: The important key players in the Global Market are – Shire-NPS Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., EnteraBio Ltd., WCCT GLOBAL INC., Takeda Pharmaceutical Company Limited, Novartis AG, GlaxoSmithKline plc., AbbVie Inc., Sun Pharmaceuticals Ltd., Teva Pharmaceuticals Ltd., Amgen Inc., and Ascendis Pharma A/S Manufacturers 5. What is the study period of this Market? Ans: The Global Market is studied from 2022 to 2029.
Hypoparathyroidism Treatment Market
1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Hypoparathyroidism Treatment Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Hypoparathyroidism Treatment Market Analysis and Forecast 6.1. Hypoparathyroidism Treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Hypoparathyroidism Treatment Market Analysis and Forecast, by Distribution channel 7.1. Introduction and Definition 7.2. Key Findings 7.3. Hypoparathyroidism Treatment Market Value Share Analysis, by Distribution channel 7.4. Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, by Distribution channel 7.5. Hypoparathyroidism Treatment Market Analysis, by Distribution channel 7.6. Hypoparathyroidism Treatment Market Attractiveness Analysis, by Distribution channel 8. Hypoparathyroidism Treatment Market Analysis and Forecast, by Root of administration 8.1. Introduction and Definition 8.2. Key Findings 8.3. Hypoparathyroidism Treatment Market Value Share Analysis, by Root of administration 8.4. Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, by Root of administration 8.5. Hypoparathyroidism Treatment Market Analysis, by Root of administration 8.6. Hypoparathyroidism Treatment Market Attractiveness Analysis, by Root of administration 9. Hypoparathyroidism Treatment Market Analysis and Forecast, by Drugs class 9.1. Introduction and Definition 9.2. Key Findings 9.3. Hypoparathyroidism Treatment Market Value Share Analysis, by Drugs class 9.4. Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, by Drugs class 9.5. Hypoparathyroidism Treatment Market Analysis, by Drugs class 9.6. Hypoparathyroidism Treatment Market Attractiveness Analysis, by Drugs class 10. Hypoparathyroidism Treatment Market Analysis, by Region 10.1. Hypoparathyroidism Treatment Market Value Share Analysis, by Region 10.2. Hypoparathyroidism Treatment Market Size (US$ Mn) Forecast, by Region 10.3. Hypoparathyroidism Treatment Market Attractiveness Analysis, by Region 11. North America Hypoparathyroidism Treatment Market Analysis 11.1. Key Findings 11.2. North America Hypoparathyroidism Treatment Market Overview 11.3. North America Hypoparathyroidism Treatment Market Value Share Analysis, by Distribution channel 11.4. North America Hypoparathyroidism Treatment Market Forecast, by Distribution channel 11.4.1. Retail pharmacy 11.4.2. Hospital pharmacy 11.4.3. Online sales 11.5. North America Hypoparathyroidism Treatment Market Value Share Analysis, by Root of administration 11.6. North America Hypoparathyroidism Treatment Market Forecast, by Root of administration 11.6.1. Oral 11.6.2. Parenteral 11.7. North America Hypoparathyroidism Treatment Market Value Share Analysis, by Drugs class 11.8. North America Hypoparathyroidism Treatment Market Forecast, by Drugs class 11.8.1. Parathyroid hormone 11.8.2. Vitamin D analogue 11.8.3. Calcium supplements 11.9. North America Hypoparathyroidism Treatment Market Value Share Analysis, by Country 11.10. North America Hypoparathyroidism Treatment Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Hypoparathyroidism Treatment Market Analysis, by Country 11.12. U.S. Hypoparathyroidism Treatment Market Forecast, by Distribution channel 11.12.1. Retail pharmacy 11.12.2. Hospital pharmacy 11.12.3. Online sales 11.13. U.S. Hypoparathyroidism Treatment Market Forecast, by Root of administration 11.13.1. Oral 11.13.2. Parenteral 11.14. U.S. Hypoparathyroidism Treatment Market Forecast, by Drugs class 11.14.1. Parathyroid hormone 11.14.2. Vitamin D analogue 11.14.3. Calcium supplements 11.15. Canada Hypoparathyroidism Treatment Market Forecast, by Distribution channel 11.15.1. Retail pharmacy 11.15.2. Hospital pharmacy 11.15.3. Online sales 11.16. Canada Hypoparathyroidism Treatment Market Forecast, by Root of administration 11.16.1. Oral 11.16.2. Parenteral 11.17. Canada Hypoparathyroidism Treatment Market Forecast, by Drugs class 11.17.1. Parathyroid hormone 11.17.2. Vitamin D analogue 11.17.3. Calcium supplements 11.18. North America Hypoparathyroidism Treatment Market Attractiveness Analysis 11.18.1. By Distribution channel 11.18.2. By Root of administration 11.18.3. By Drugs class 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Hypoparathyroidism Treatment Market Analysis 12.1. Key Findings 12.2. Europe Hypoparathyroidism Treatment Market Overview 12.3. Europe Hypoparathyroidism Treatment Market Value Share Analysis, by Distribution channel 12.4. Europe Hypoparathyroidism Treatment Market Forecast, by Distribution channel 12.4.1. Retail pharmacy 12.4.2. Hospital pharmacy 12.4.3. Online sales 12.5. Europe Hypoparathyroidism Treatment Market Value Share Analysis, by Root of administration 12.6. Europe Hypoparathyroidism Treatment Market Forecast, by Root of administration 12.6.1. Oral 12.6.2. Parenteral 12.7. Europe Hypoparathyroidism Treatment Market Value Share Analysis, by Drugs class 12.8. Europe Hypoparathyroidism Treatment Market Forecast, by Drugs class 12.8.1. Parathyroid hormone 12.8.2. Vitamin D analogue 12.8.3. Calcium supplements 12.9. Europe Hypoparathyroidism Treatment Market Value Share Analysis, by Country 12.10. Europe Hypoparathyroidism Treatment Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Hypoparathyroidism Treatment Market Analysis, by Country 12.12. Germany Hypoparathyroidism Treatment Market Forecast, by Distribution channel 12.12.1. Retail pharmacy 12.12.2. Hospital pharmacy 12.12.3. Online sales 12.13. Germany Hypoparathyroidism Treatment Market Forecast, by Root of administration 12.13.1. Oral 12.13.2. Parenteral 12.14. Germany Hypoparathyroidism Treatment Market Forecast, by Drugs class 12.14.1. Parathyroid hormone 12.14.2. Vitamin D analogue 12.14.3. Calcium supplements 12.15. U.K. Hypoparathyroidism Treatment Market Forecast, by Distribution channel 12.15.1. Retail pharmacy 12.15.2. Hospital pharmacy 12.15.3. Online sales 12.16. U.K. Hypoparathyroidism Treatment Market Forecast, by Root of administration 12.16.1. Oral 12.16.2. Parenteral 12.17. U.K. Hypoparathyroidism Treatment Market Forecast, by Drugs class 12.17.1. Parathyroid hormone 12.17.2. Vitamin D analogue 12.17.3. Calcium supplements 12.18. France Hypoparathyroidism Treatment Market Forecast, by Distribution channel 12.18.1. Retail pharmacy 12.18.2. Hospital pharmacy 12.18.3. Online sales 12.19. France Hypoparathyroidism Treatment Market Forecast, by Root of administration 12.19.1. Oral 12.19.2. Parenteral 12.20. France Hypoparathyroidism Treatment Market Forecast, by Drugs class 12.20.1. Parathyroid hormone 12.20.2. Vitamin D analogue 12.20.3. Calcium supplements 12.21. Italy Hypoparathyroidism Treatment Market Forecast, by Distribution channel 12.21.1. Retail pharmacy 12.21.2. Hospital pharmacy 12.21.3. Online sales 12.22. Italy Hypoparathyroidism Treatment Market Forecast, by Root of administration 12.22.1. Oral 12.22.2. Parenteral 12.23. Italy Hypoparathyroidism Treatment Market Forecast, by Drugs class 12.23.1. Parathyroid hormone 12.23.2. Vitamin D analogue 12.23.3. Calcium supplements 12.24. Spain Hypoparathyroidism Treatment Market Forecast, by Distribution channel 12.24.1. Retail pharmacy 12.24.2. Hospital pharmacy 12.24.3. Online sales 12.25. Spain Hypoparathyroidism Treatment Market Forecast, by Root of administration 12.25.1. Oral 12.25.2. Parenteral 12.26. Spain Hypoparathyroidism Treatment Market Forecast, by Drugs class 12.26.1. Parathyroid hormone 12.26.2. Vitamin D analogue 12.26.3. Calcium supplements 12.27. Rest of Europe Hypoparathyroidism Treatment Market Forecast, by Distribution channel 12.27.1. Retail pharmacy 12.27.2. Hospital pharmacy 12.27.3. Online sales 12.28. Rest of Europe Hypoparathyroidism Treatment Market Forecast, by Root of administration 12.28.1. Oral 12.28.2. Parenteral 12.29. Rest Of Europe Hypoparathyroidism Treatment Market Forecast, by Drugs class 12.29.1. Parathyroid hormone 12.29.2. Vitamin D analogue 12.29.3. Calcium supplements 12.30. Europe Hypoparathyroidism Treatment Market Attractiveness Analysis 12.30.1. By Distribution channel 12.30.2. By Root of administration 12.30.3. By Drugs class 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Hypoparathyroidism Treatment Market Analysis 13.1. Key Findings 13.2. Asia Pacific Hypoparathyroidism Treatment Market Overview 13.3. Asia Pacific Hypoparathyroidism Treatment Market Value Share Analysis, by Distribution channel 13.4. Asia Pacific Hypoparathyroidism Treatment Market Forecast, by Distribution channel 13.4.1. Retail pharmacy 13.4.2. Hospital pharmacy 13.4.3. Online sales 13.5. Asia Pacific Hypoparathyroidism Treatment Market Value Share Analysis, by Root of administration 13.6. Asia Pacific Hypoparathyroidism Treatment Market Forecast, by Root of administration 13.6.1. Oral 13.6.2. Parenteral 13.7. Asia Pacific Hypoparathyroidism Treatment Market Value Share Analysis, by Drugs class 13.8. Asia Pacific Hypoparathyroidism Treatment Market Forecast, by Drugs class 13.8.1. Parathyroid hormone 13.8.2. Vitamin D analogue 13.8.3. Calcium supplements 13.9. Asia Pacific Hypoparathyroidism Treatment Market Value Share Analysis, by Country 13.10. Asia Pacific Hypoparathyroidism Treatment Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Hypoparathyroidism Treatment Market Analysis, by Country 13.12. China Hypoparathyroidism Treatment Market Forecast, by Distribution channel 13.12.1. Retail pharmacy 13.12.2. Hospital pharmacy 13.12.3. Online sales 13.13. China Hypoparathyroidism Treatment Market Forecast, by Root of administration 13.13.1. Oral 13.13.2. Parenteral 13.14. China Hypoparathyroidism Treatment Market Forecast, by Drugs class 13.14.1. Parathyroid hormone 13.14.2. Vitamin D analogue 13.14.3. Calcium supplements 13.15. India Hypoparathyroidism Treatment Market Forecast, by Distribution channel 13.15.1. Retail pharmacy 13.15.2. Hospital pharmacy 13.15.3. Online sales 13.16. India Hypoparathyroidism Treatment Market Forecast, by Root of administration 13.16.1. Oral 13.16.2. Parenteral 13.17. India Hypoparathyroidism Treatment Market Forecast, by Drugs class 13.17.1. Parathyroid hormone 13.17.2. Vitamin D analogue 13.17.3. Calcium supplements 13.18. Japan Hypoparathyroidism Treatment Market Forecast, by Distribution channel 13.18.1. Retail pharmacy 13.18.2. Hospital pharmacy 13.18.3. Online sales 13.19. Japan Hypoparathyroidism Treatment Market Forecast, by Root of administration 13.19.1. Oral 13.19.2. Parenteral 13.20. Japan Hypoparathyroidism Treatment Market Forecast, by Drugs class 13.20.1. Parathyroid hormone 13.20.2. Vitamin D analogue 13.20.3. Calcium supplements 13.21. ASEAN Hypoparathyroidism Treatment Market Forecast, by Distribution channel 13.21.1. Retail pharmacy 13.21.2. Hospital pharmacy 13.21.3. Online sales 13.22. ASEAN Hypoparathyroidism Treatment Market Forecast, by Root of administration 13.22.1. Oral 13.22.2. Parenteral 13.23. ASEAN Hypoparathyroidism Treatment Market Forecast, by Drugs class 13.23.1. Parathyroid hormone 13.23.2. Vitamin D analogue 13.23.3. Calcium supplements 13.24. Rest of Asia Pacific Hypoparathyroidism Treatment Market Forecast, by Distribution channel 13.24.1. Retail pharmacy 13.24.2. Hospital pharmacy 13.24.3. Online sales 13.25. Rest of Asia Pacific Hypoparathyroidism Treatment Market Forecast, by Root of administration 13.25.1. Oral 13.25.2. Parenteral 13.26. Rest of Asia Pacific Hypoparathyroidism Treatment Market Forecast, by Drugs class 13.26.1. Parathyroid hormone 13.26.2. Vitamin D analogue 13.26.3. Calcium supplements 13.27. Asia Pacific Hypoparathyroidism Treatment Market Attractiveness Analysis 13.27.1. By Distribution channel 13.27.2. By Root of administration 13.27.3. By Drugs class 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Hypoparathyroidism Treatment Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Hypoparathyroidism Treatment Market Overview 14.3. Middle East & Africa Hypoparathyroidism Treatment Market Value Share Analysis, by Distribution channel 14.4. Middle East & Africa Hypoparathyroidism Treatment Market Forecast, by Distribution channel 14.4.1. Retail pharmacy 14.4.2. Hospital pharmacy 14.4.3. Online sales 14.5. Middle East & Africa Hypoparathyroidism Treatment Market Value Share Analysis, by Root of administration 14.6. Middle East & Africa Hypoparathyroidism Treatment Market Forecast, by Root of administration 14.6.1. Oral 14.6.2. Parenteral 14.7. Middle East & Africa Hypoparathyroidism Treatment Market Value Share Analysis, by Drugs class 14.8. Middle East & Africa Hypoparathyroidism Treatment Market Forecast, by Drugs class 14.8.1. Parathyroid hormone 14.8.2. Vitamin D analogue 14.8.3. Calcium supplements 14.9. Middle East & Africa Hypoparathyroidism Treatment Market Value Share Analysis, by Country 14.10. Middle East & Africa Hypoparathyroidism Treatment Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Hypoparathyroidism Treatment Market Analysis, by Country 14.12. GCC Hypoparathyroidism Treatment Market Forecast, by Distribution channel 14.12.1. Retail pharmacy 14.12.2. Hospital pharmacy 14.12.3. Online sales 14.13. GCC Hypoparathyroidism Treatment Market Forecast, by Root of administration 14.13.1. Oral 14.13.2. Parenteral 14.14. GCC Hypoparathyroidism Treatment Market Forecast, by Drugs class 14.14.1. Parathyroid hormone 14.14.2. Vitamin D analogue 14.14.3. Calcium supplements 14.15. South Africa Hypoparathyroidism Treatment Market Forecast, by Distribution channel 14.15.1. Retail pharmacy 14.15.2. Hospital pharmacy 14.15.3. Online sales 14.16. South Africa Hypoparathyroidism Treatment Market Forecast, by Root of administration 14.16.1. Oral 14.16.2. Parenteral 14.17. South Africa Hypoparathyroidism Treatment Market Forecast, by Drugs class 14.17.1. Parathyroid hormone 14.17.2. Vitamin D analogue 14.17.3. Calcium supplements 14.18. Rest of Middle East & Africa Hypoparathyroidism Treatment Market Forecast, by Distribution channel 14.18.1. Retail pharmacy 14.18.2. Hospital pharmacy 14.18.3. Online sales 14.19. Rest of Middle East & Africa Hypoparathyroidism Treatment Market Forecast, by Root of administration 14.19.1. Oral 14.19.2. Parenteral 14.20. Rest of Middle East & Africa Hypoparathyroidism Treatment Market Forecast, by Drugs class 14.20.1. Parathyroid hormone 14.20.2. Vitamin D analogue 14.20.3. Calcium supplements 14.21. Middle East & Africa Hypoparathyroidism Treatment Market Attractiveness Analysis 14.21.1. By Distribution channel 14.21.2. By Root of administration 14.21.3. By Drugs class 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Hypoparathyroidism Treatment Market Analysis 15.1. Key Findings 15.2. South America Hypoparathyroidism Treatment Market Overview 15.3. South America Hypoparathyroidism Treatment Market Value Share Analysis, by Distribution channel 15.4. South America Hypoparathyroidism Treatment Market Forecast, by Distribution channel 15.4.1. Retail pharmacy 15.4.2. Hospital pharmacy 15.4.3. Online sales 15.5. South America Hypoparathyroidism Treatment Market Value Share Analysis, by Root of administration 15.6. South America Hypoparathyroidism Treatment Market Forecast, by Root of administration 15.6.1. Oral 15.6.2. Parenteral 15.7. South America Hypoparathyroidism Treatment Market Value Share Analysis, by Drugs class 15.8. South America Hypoparathyroidism Treatment Market Forecast, by Drugs class 15.8.1. Parathyroid hormone 15.8.2. Vitamin D analogue 15.8.3. Calcium supplements 15.9. South America Hypoparathyroidism Treatment Market Value Share Analysis, by Country 15.10. South America Hypoparathyroidism Treatment Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Hypoparathyroidism Treatment Market Analysis, by Country 15.12. Brazil Hypoparathyroidism Treatment Market Forecast, by Distribution channel 15.12.1. Retail pharmacy 15.12.2. Hospital pharmacy 15.12.3. Online sales 15.13. Brazil Hypoparathyroidism Treatment Market Forecast, by Root of administration 15.13.1. Oral 15.13.2. Parenteral 15.14. Brazil Hypoparathyroidism Treatment Market Forecast, by Drugs class 15.14.1. Parathyroid hormone 15.14.2. Vitamin D analogue 15.14.3. Calcium supplements 15.15. Mexico Hypoparathyroidism Treatment Market Forecast, by Distribution channel 15.15.1. Retail pharmacy 15.15.2. Hospital pharmacy 15.15.3. Online sales 15.16. Mexico Hypoparathyroidism Treatment Market Forecast, by Root of administration 15.16.1. Oral 15.16.2. Parenteral 15.17. Mexico Hypoparathyroidism Treatment Market Forecast, by Drugs class 15.17.1. Parathyroid hormone 15.17.2. Vitamin D analogue 15.17.3. Calcium supplements 15.18. Rest of South America Hypoparathyroidism Treatment Market Forecast, by Distribution channel 15.18.1. Retail pharmacy 15.18.2. Hospital pharmacy 15.18.3. Online sales 15.19. Rest of South America Hypoparathyroidism Treatment Market Forecast, by Root of administration 15.19.1. Oral 15.19.2. Parenteral 15.20. Rest of South America Hypoparathyroidism Treatment Market Forecast, by Drugs class 15.20.1. Parathyroid hormone 15.20.2. Vitamin D analogue 15.20.3. Calcium supplements 15.21. South America Hypoparathyroidism Treatment Market Attractiveness Analysis 15.21.1. By Distribution channel 15.21.2. By Root of administration 15.21.3. By Drugs class 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Shire-NPS Pharmaceuticals, Inc. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Manufacturing Footprint 16.3.2. F. Hoffmann-La Roche Ltd. 16.3.3. EnteraBio Ltd. 16.3.4. WCCT INC. 16.3.5. Takeda Pharmaceutical Company Limited 16.3.6. Novartis AG 16.3.7. GlaxoSmithKline plc 16.3.8. AbbVie Inc. 16.3.9. Sun Pharmaceuticals Ltd. 16.3.10. Teva Pharmaceuticals Ltd. 16.3.11. Amgen Inc. 16.3.12. Ascendis Pharma A/S Manufacturers 17. Primary Key Insights